

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM784265

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
OrbiMed Royalty & Credit Opportunities III, LP		01/03/2023	Limited Partnership: DELAWARE

RECEIVING PARTY DATA

Name:	Oyster Point Pharma, Inc.
Street Address:	202 Carnegie Center Drive, Suite 109
City:	Princeton
State/Country:	NEW JERSEY
Postal Code:	08540
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 15

Property Type	Number	Word Mark
Serial Number:	88828629	AHVIA
Serial Number:	90581634	DRY EYELAND
Serial Number:	90581636	DRY EYELAND
Serial Number:	88791718	EZVAYA
Serial Number:	88570643	OYSTER POINT
Serial Number:	88570636	OYSTER POINT
Serial Number:	88570647	OYSTER POINT
Serial Number:	88570646	OYSTER POINT
Serial Number:	88872998	TIFIMEO
Serial Number:	88791704	TIRVAYA
Serial Number:	88818863	TYRLIBRIA
Serial Number:	90255562	TYRLIBRIA
Serial Number:	88791721	TYRNAU
Serial Number:	88791700	TYRVAYA
Serial Number:	88873736	TYRVAYA

CORRESPONDENCE DATA

Fax Number: 4156932222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

TRADEMARK

REEL: 007959 FRAME: 0789

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000
Email: crhem@cooley.com
Correspondent Name: Cooley LLP
Address Line 1: 3 Embarcadero Center, 20th Floor
Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	328567-107
--------------------------------	------------

NAME OF SUBMITTER:	C. Rhem
---------------------------	---------

SIGNATURE:	/CR/
-------------------	------

DATE SIGNED:	02/02/2023
---------------------	------------

Total Attachments: 4

source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page1.tif

source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page2.tif

source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page3.tif

source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page4.tif

TERMINATION TO TRADEMARK SECURITY AGREEMENT

This **TERMINATION TO TRADEMARK SECURITY AGREEMENT** (this "*Termination*"), dated as of January 3, 2023, is executed by OrbiMed Royalty & Credit Opportunities III, LP ("*Administrative Agent*"), with an address at 601 Lexington Avenue, 54th Floor, New York, NY 10022, in favor of Oyster Point Pharma, Inc., a Delaware corporation ("*Grantor*"), with an address at 202 Carnegie Center Drive, Suite 109, Princeton, NJ 08540.

RECITALS

WHEREAS, Grantor and Administrative Agent entered into that certain Security Agreement, dated as of August 5, 2021 (as amended or otherwise modified from time to time, the "*Security Agreement*");

WHEREAS, in connection with the Security Agreement, Grantor and Administrative Agent entered into that certain Trademark Security Agreement dated as of August 5, 2021 (as amended or otherwise modified from time to time, the "*Agreement*") pursuant to which Grantor granted to Administrative Agent a security interest in the Trademark Collateral (as defined in the Agreement); and

WHEREAS, Administrative Agent has agreed to terminate and release its security interest in the Trademark Collateral as herein provided.

NOW, THEREFORE, in consideration of the foregoing, Administrative Agent agrees as follows:

1. Administrative Agent hereby terminates its security interest in the Trademark Collateral, including without limitation the trademarks listed on *Schedule 1* hereto, which security interest was evidenced by the recordation of the Security Agreement with the United States Patent and Trademark Office on August 16, 2021, in Reel/Frame 7393/0031.
2. Administrative Agent may record this Termination with the United States Patent and Trademark Office at the expense of Grantor.
3. Administrative Agent hereby irrevocably authorizes Grantor or Grantor's agent to record this Termination with the United States Patent and Trademark Office and any other relevant governmental authority.
4. This Termination and the rights and obligations of the parties under this Termination shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, Administrative Agent has executed this Termination on the date first written above.

ADMINISTRATIVE AGENT:

ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP

By: OrbiMed ROF III LLC, its general partner
By: OrbiMed Advisors LLC, its Managing Member

By _____
Name: DocuSigned by: Matthew Rizzo
B10589F5612B4B7...
Title: Member



SCHEDULE 1
to the Termination to Trademark Security Agreement


TRADEMARKS

Trademark Registrations

None.

Trademark Applications

<u>Grantor</u>	<u>Jurisdiction</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Mark</u>
Oyster Point Pharma, Inc.	United States	Application No. 88828629	Filed Mar-10-2020	AHVIA
Oyster Point Pharma, Inc.	United States	Application No. 90581634	Filed Mar-16-2021	DRY EYELAND
Oyster Point Pharma, Inc.	United States	Application No. 90581636	Filed Mar-16-2021	DRY EYELAND
Oyster Point Pharma, Inc.	United States	Application No. 88791718	Filed Feb-10-2020	EZVAYA
Oyster Point Pharma, Inc.	United States	Application No. 88570643	Filed Aug-07-2019	OYSTER POINT
Oyster Point Pharma, Inc.	United States	Application No. 88570636	Filed Aug-07-2019	OYSTER POINT
Oyster Point Pharma, Inc.	United States	Application No. 88570647	Filed Aug-07-2019	OYSTER POINT & Circle Design 
Oyster Point Pharma, Inc.	United States	Application No. 88570646	Filed Aug-07-2019	OYSTER POINT & Circle Design 
Oyster Point Pharma, Inc.	United States	Application No. 88872998	Filed Apr-15-2020	TIFIMEO
Oyster Point Pharma, Inc.	United States	Application No. 88791704	Filed Feb-10-2020	TIRVAYA

Oyster Point Pharma, Inc.	United States	Application No. 88818863	Filed Mar-03-2020	TYRLIBRIA
Oyster Point Pharma, Inc.	United States	Application No. 90255562	Filed Oct-14-2020	TYRLIBRIA & Droplet Design 
Oyster Point Pharma, Inc.	United States	Application No. 88791721	Filed Feb-10-2020	TYRNAU
Oyster Point Pharma, Inc.	United States	Application No. 88791700	Filed Feb-10-2020	TYRVAYA
Oyster Point Pharma, Inc.	United States	Application No. 88873736	Filed Apr-15-2020	TYRVAYA & Droplet Design 